Published in Blood Weekly, April 20th, 2000
The company's AlloMune Cancer System is being designed to re-educate the body's immune system to accept foreign cells with the potential to produce powerful anti-tumor effects and minimize the occurrence of severe graft-versus-host disease (GvHD).
The trial is built on the success of a prototype AlloMune System, which has been used at The Massachusetts General Hospital...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.